MINI FUTURE LONG - NOVO-NORDISK B | Real-time Euronext Paris 05:48:37 2024-05-17 EDT | ||
| 2.575 EUR | -4.28% |
|
| Current month | +10.93% | ||
| 1 month | +28.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 2.575 | -4.28% |
| 24-05-16 | 2.69 | -2.54% |
| 24-05-15 | 2.76 | +3.37% |
| 24-05-14 | 2.67 | +1.14% |
| 24-05-13 | 2.64 | +18.39% |
Real-time Euronext Paris
Last update May 17, 2024 at 05:48 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| YH5NB | |
| ISIN | NLBNPNL2OO38 |
| Date issued | 2024-03-11 |
| Strike | 715.9 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.72 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.905 € |
|---|---|
| Lowest since issue | 1.57 € |
| Spread | 0.01 € |
| Spread % | 0.39% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
912.9
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.40%
- Stock Market
- Certificates
- YH5NB Certificat
